A landmark in drug discovery based on complex natural product synthesis

被引：29

作者：

Kawano, Satoshi ^{[1
]}

Ito, Ken ^{[1
]}

Yahata, Kenzo ^{[2
]}

Kira, Kazunobu ^{[1
]}

Abe, Takanori ^{[1
]}

Akagi, Tsuyoshi ^{[1
]}

Asano, Makoto ^{[1
]}

Iso, Kentaro ^{[1
]}

Sato, Yuki ^{[1
]}

Matsuura, Fumiyoshi ^{[3
]}

Ohashi, Isao ^{[1
]}

Matsumoto, Yasunobu ^{[1
]}

Isomura, Minetaka ^{[1
]}

Sasaki, Takeo ^{[1
]}

Fukuyama, Takashi ^{[1
]}

Miyashita, Yusuke ^{[4
]}

Kaburagi, Yosuke ^{[1
]}

Yokoi, Akira ^{[1
]}

Asano, Osamu ^{[1
]}

Owa, Takashi ^{[5
]}

Kishi, Yoshito ^{[2
]}

机构：

[1] Eisai & Co Ltd, Tsukuba, Ibaraki, Japan

[2] Harvard Univ, Cambridge, MA 02138 USA

[3] Eisai & Co Ltd, Bunkyo Ku, Tokyo, Japan

[4] Eisai & Co Ltd, Kamisu, Ibaraki, Japan

[5] Eisai Inc, Woodcliff Lake, NJ USA

来源：

SCIENTIFIC REPORTS | 2019年 / 9卷 / 1期

关键词：

ANTITUMOR POLYETHER MACROLIDES; ANTINEOPLASTIC AGENTS; HALICHONDRIN-B; BREAST-CANCER; TUBULIN; ANTIBODY; MICROTUBULES; CETUXIMAB; DISEASE; BINDING;

D O I：

10.1038/s41598-019-45001-9

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Despite their outstanding antitumour activity in mice, the limited supply from the natural sources has prevented drug discovery/development based on intact halichondrins. We achieved a total synthesis of C52-halichondrin-B amine (E7130) on a >10 g scale with >99.8% purity under GMP conditions. Interestingly, E7130 not only is a novel microtubule dynamics inhibitor but can also increase intratumoural CD31-positive endothelial cells and reduce alpha-SMA-positive cancer-associated fibroblasts at pharmacologically relevant compound concentrations. According to these unique effects, E7130 significantly augment the effect of antitumour treatments in mouse models and is currently in a clinical trial. Overall, our work demonstrates that a total synthesis can address the issue of limited material supply in drug discovery/development even for the cases of complex natural products.

引用

页数：9

共 50 条

[1] A landmark in drug discovery based on complex natural product synthesis
Satoshi Kawano
Ken Ito
Kenzo Yahata
Kazunobu Kira
Takanori Abe
Tsuyoshi Akagi
Makoto Asano
Kentaro Iso
Yuki Sato
Fumiyoshi Matsuura
Isao Ohashi
Yasunobu Matsumoto
Minetaka Isomura
Takeo Sasaki
Takashi Fukuyama
Yusuke Miyashita
Yosuke Kaburagi
Akira Yokoi
Osamu Asano
Takashi Owa
Yoshito Kishi
Scientific Reports, 9
[2] Natural Product-Based Drug Discovery
Li, Rongshi
MEDICINAL RESEARCH REVIEWS, 2016, 36 (01) : 3 - 3
[3] Cheminformatics in Natural Product-Based Drug Discovery
Chen, Ya
Kirchmair, Johannes
MOLECULAR INFORMATICS, 2020, 39 (12)
[4] Bridging the gap between natural product synthesis and drug discovery
Truax, Nathanyal J.
Romo, Daniel
NATURAL PRODUCT REPORTS, 2020, 37 (11) : 1436 - 1453
[5] Biodiversity and natural product drug discovery
Mahidol, C
Ruchirawat, S
Prawat, H
Pisutjaroenpong, S
Engprasert, S
Chumsri, P
Tengchaisri, T
Sirisinha, S
Picha, P
PURE AND APPLIED CHEMISTRY, 1998, 70 (11) : 2065 - 2072
[6] Natural product chemistry for drug discovery
Seiji Hashimoto
The Journal of Antibiotics, 2011, 64 (10) : 697 - 697
[7] Tools for drug discovery: Natural product-based libraries
Grabley, S
Thiericke, R
Sattler, I
ROLE OF NATURAL PRODUCTS IN DRUG DISCOVERY, 2000, 32 : 217 - 252
[8] Introduction: Natural product-based drug discovery in Immunopharmacology
Abe, Fuminori
Marceau, Francois
Talmadge, James E.
INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 37 : 1 - 2
[9] Synthesis of Four Novel Natural Product Inspired Scaffolds for Drug Discovery
Jenkins, Ian D.
Lacrampe, Fabienne
Ripper, Justin
Alcaraz, Lilian
Van Le, Phuc
Nikolakopoulos, George
Leone, Priscila de Almeida
White, Rodney H.
Quinn, Ronald J.
JOURNAL OF ORGANIC CHEMISTRY, 2009, 74 (03): : 1304 - 1313
[10] A case history in natural product-based drug discovery: discovery of vorapaxar (Zontivity™)
Samuel Chackalamannil
Medicinal Chemistry Research, 2022, 31 : 1623 - 1636

← 1 2 3 4 5 →